FDA reviews AstraZeneca’s Saphnelo for subcutaneous use in Lupus
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The study evaluated patients with stage III/IV melanoma after complete tumor resection
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
Subscribe To Our Newsletter & Stay Updated